Komen’s Investment in MBC Research
We must understand the biology of breast cancer and metastasis to develop drugs to slow, stop and prevent it. Metastatic breast cancers, by and large, are more resistant to the standard therapies we have today. That’s why it’s going to take innovative research and breakthrough discoveries to detect, target and find the cures for this disease. Susan G. Komen has invested more than $210 million in MBC research, supporting more than 500 research grants, including more then 50 clinical trials.
“Without Komen funding we would lose the next generation of breast cancer researchers.”
Dr. George Sledge, Komen Chief Scientific Advisor
Current Research Projects
Clinical trials offer people an opportunity to try new treatments that are not, yet FDA approved and/or not available to the general public.
Find a Clinical Trial or call our Clinical Trial Information Helpline at 877-465-6636.